×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RDY – dr. reddy's laboratories ltd (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RDY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
03:01 am
rdy
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/7
03:01 pm
rdy
Pulmonary Arterial Hypertension Drugs Market to Grow by USD 2.26 Billion from 2024-2028, as Rising PAH Prevalence Drives Demand with AI Redefining Market Landscape - Technavio [Yahoo! Finance]
Low
Report
Pulmonary Arterial Hypertension Drugs Market to Grow by USD 2.26 Billion from 2024-2028, as Rising PAH Prevalence Drives Demand with AI Redefining Market Landscape - Technavio [Yahoo! Finance]
11/6
11:24 am
rdy
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow [Yahoo! Finance]
Low
Report
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow [Yahoo! Finance]
11/6
09:30 am
rdy
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.
Low
Report
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.
11/6
02:22 am
rdy
Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/5
11:06 pm
rdy
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
11/4
03:01 pm
rdy
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market Landscape - Technavio [Yahoo! Finance]
Low
Report
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market Landscape - Technavio [Yahoo! Finance]
10/25
07:44 am
rdy
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year [Yahoo! Finance]
Low
Report
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:03 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-0.7%
dr. reddy's laboratories ltd
11/5/2024
04:02 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
0.3%
dr. reddy's laboratories ltd
7/29/2024
04:01 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-1.1%
dr. reddy's laboratories ltd
7/28/2024
06:05 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-1.1%
dr. reddy's laboratories ltd
Date
Time
Symbol
Headline
Impact
11/14
07:11 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Nov 14
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Nov 14
11/12
09:24 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Nov 11
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Nov 11
11/7
06:35 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Nov 06
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Nov 06
11/6
06:12 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Nov 06
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Nov 06
11/6
06:05 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Nov 05
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Nov 05
11/4
12:11 pm
rdy
Form 6-K DR REDDYS LABORATORIES For: Nov 04
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Nov 04
10/29
10:53 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Oct 29
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Oct 29
10/29
06:03 am
rdy
Form EFFECT DR REDDYS LABORATORIES
Low
Report
Form EFFECT DR REDDYS LABORATORIES
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Dr.Reddy's Laboratories Ltd (NYSE: RDY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating.
6.2%
1/27 Form 6-K DR REDDYS LABORATORIES For: Jan 27 5.3%
4/9 Form SC 13G/A DR REDDYS LABORATORIES Filed by: BlackRock Inc. 4.8%
3/20 Dr. Reddy's launches pyrimethamine tablets in U.S. [Seeking Alpha] 3.9%
3/17 Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market 3.0%
10/23 Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market 2.8%
7/29 Dr. Reddy's Laboratories Limited 2020 Q1 - Results - Earnings Call Slides [Seeking Alpha] 2.8%
9/11 Hazmat situation reported at Dr. Reddy's New York facility [Seeking Alpha] 2.8%
5/20 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A 2.7%
9/9 Form SC 13G DR REDDYS LABORATORIES Filed by: COMMONWEALTH BANK OF AUSTRALIA 2.4%
1/27 Form 6-K DR REDDYS LABORATORIES For: Jan 27 5.3%
4/9 Form SC 13G/A DR REDDYS LABORATORIES Filed by: BlackRock Inc. 4.8%
3/20 Dr. Reddy's launches pyrimethamine tablets in U.S. [Seeking Alpha] 3.9%
3/17 Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market 3.0%
10/23 Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market 2.8%
7/29 Dr. Reddy's Laboratories Limited 2020 Q1 - Results - Earnings Call Slides [Seeking Alpha] 2.8%
9/11 Hazmat situation reported at Dr. Reddy's New York facility [Seeking Alpha] 2.8%
5/20 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A 2.7%
9/9 Form SC 13G DR REDDYS LABORATORIES Filed by: COMMONWEALTH BANK OF AUSTRALIA 2.4%
TOP News Decliners
3/12
Form 6-K DR REDDYS LABORATORIES For: Mar 12
-6.6%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -6.0%
3/16 Form 6-K DR REDDYS LABORATORIES For: Mar 14 -4.6%
7/29 Dr. Reddy’s Q1 FY20 Financial Results -3.3%
7/29 Q1/2020 6/30/2019 EPS 39.910 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
7/23 Form 6-K DR REDDYS LABORATORIES For: Jul 23 -2.5%
2/27 Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market -2.3%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -1.9%
10/23 Dr. Reddy's is recalling some products used to treat heartburn [CNN] -1.8%
11/22 Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market -1.7%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -6.0%
3/16 Form 6-K DR REDDYS LABORATORIES For: Mar 14 -4.6%
7/29 Dr. Reddy’s Q1 FY20 Financial Results -3.3%
7/29 Q1/2020 6/30/2019 EPS 39.910 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
7/23 Form 6-K DR REDDYS LABORATORIES For: Jul 23 -2.5%
2/27 Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market -2.3%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -1.9%
10/23 Dr. Reddy's is recalling some products used to treat heartburn [CNN] -1.8%
11/22 Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: